Psychedelic research timeline
Borderline Personality Disorder (BPD): the psychedelic research timeline
BPD has only recently moved from trait-level observations into diagnosis-specific psychedelic trials. The current record is a handful of small studies, several with comorbid depression or PTSD.
Milestones are editorially selected from Blossom’s research catalogue. Future markers are limited to important trials with dated public guidance and are shown as planned, not promised.
Hover any marker to preview its callout on the canvas, then click to pin it. Pinned is what stays open, fills this panel with the full context and links, and is what an export captures. Landmarks stay labelled on the canvas so the exported image reads on its own.
Download the artifact
Exports rasterise the live SVG, so whatever you have toggled is what you get.
An emotion-regulation signal
2018 to 2021Observational ayahuasca data generates a hypothesis rather than efficacy evidence.2018-11
Emotion dysregulation improves in an observational study
Ayahuasca-associated improvements are reported in people with borderline-like traits. The sample is observational and not a BPD treatment trial.
The first BPD trials
2022 onwardsPsilocybin, MDMA and ketamine enter small diagnosis-specific studies.2022-09
The first BPD psilocybin study opens
A Phase II study tests psilocybin in people with co-occurring major depression and BPD.
2024-07
A co-occurring PTSD–BPD MDMA pilot is registered
A controlled before-and-after pilot proposes MDMA-assisted psychotherapy for PTSD in people with co-occurring BPD.
2025-02
A dedicated MDMA–BPD trial recruits
A Phase II study begins recruiting people with BPD for MDMA treatment.
2025-11
BorderKET is registered
A Phase II pilot proposes ketamine infusion for symptomatic improvement in severe BPD.
2026-04
The first open-label psilocybin result reports
An open-label study reports single-dose psilocybin for BPD with co-occurring MDD. The absence of a control group keeps the conclusion preliminary.
Borderline Personality Disorder (BPD)
A very new clinical record across psilocybin, MDMA and ketamine
Research Landscape
What the registered trials connected to Borderline Personality Disorder (BPD) look like when you line them up. Counts come from Blossom’s trial records as of August 2026.
What's live right now, and what stopped?
SourcedRegistry status of all 5 Borderline Personality Disorder (BPD) trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Publication Landscape
How the 12 papers Blossom links to Borderline Personality Disorder (BPD) line up by year, compound and journal. This is the psychedelic-relevant literature in Blossom's records as of August 2026, not the condition's full medical literature.
How has Borderline Personality Disorder (BPD) research grown?
SourcedTracked papers by publication year; 1 earlier paper published before 2012. Click a year for the running total.
Don't read as total output: only the 12 of 12 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
Which compounds shape Borderline Personality Disorder (BPD)?
SourcedTracked papers per compound. Orange marks the largest literature.
A paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.
Where is Borderline Personality Disorder (BPD) research published?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; papers without a journal on file are omitted. Blossom tracks psychedelic-relevant papers rather than each journal's full catalogue.